Rule 12 of Annex VIII to Regulation (EU) 2017/745 classifies active devices intended to administer medicinal products, body liquids, or other substances to the body, or to remove them from the body. The default class is IIa. The rule escalates to Class IIb when administration or removal is carried out in a potentially hazardous way, taking account of the nature of the substances involved, the part of the body concerned, and the mode of application. Infusion pumps, dialysis machines, insulin pumps, and anaesthesia delivery systems typically fall under Rule 12. The MDR classification Rule 12 analysis is governed by Article 51 and interpreted in MDCG 2021-24 (October 2021).

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • MDR classification Rule 12 applies to active devices that administer medicinal products, body liquids, or other substances to the body, or remove them from the body. The default class is IIa.
  • Rule 12 escalates to Class IIb when the administration or removal is potentially hazardous, judged against the nature of the substance, the part of the body, and the mode of application. The judgment is structured, not arbitrary.
  • Infusion pumps, dialysis machines, insulin pumps, enteral feeding pumps, anaesthesia delivery systems, and suction units are the canonical Rule 12 devices. Most land at Class IIb once the hazard analysis is done honestly.
  • Rule 12 sits next to the combination product boundary in Article 1(8)-(9). When the medicinal product is integral and principal, the product is a medicinal product regulated under Directive 2001/83/EC, not a device under the MDR.
  • Classification is governed by Article 51 of Regulation (EU) 2017/745, and the authoritative interpretation guide for classification is MDCG 2021-24 (October 2021). Document the Rule 12 decision with a specific intended purpose, a specific substance, a specific body site, and a specific mode of application.

Why Rule 12 matters for startups building delivery and removal devices

Every founder building an infusion pump, a wearable insulin delivery device, a dialysis unit, an enteral feeding pump, a suction device, or any other active product that moves substances into or out of the body meets Rule 12 on day one of the classification work. The question is never whether Rule 12 applies. The question is whether the administration or removal is "potentially hazardous" in the Rule 12 sense, and therefore whether the device is Class IIa or Class IIb.

That one judgment shifts the conformity assessment depth, the clinical evidence burden, and several quarters of runway. It also tends to be where founders guess. A founder who has been told "infusion pumps are IIb" usually has not read the rule text and cannot defend the class under questioning. A founder who has been told "ours is IIa because the drug is saline" is usually wrong for a different reason. Rule 12 rewards the startups that read the text, work through the three criteria, and write the decision down. This post is the walkthrough.

What Rule 12 actually says

Rule 12 of Annex VIII, Section 3 (Chapter III — Active devices) of Regulation (EU) 2017/745 reads, in substance:

All active devices intended to administer and/or remove medicinal products, body liquids or other substances to or from the body are classified as Class IIa, unless this is done in a manner that is potentially hazardous, taking account of the nature of the substances involved, of the part of the body concerned and of the mode of application, in which case they are classified as Class IIb. (Regulation (EU) 2017/745, Annex VIII, Rule 12.)

Two things are doing the work here. First, the device has to be active — powered by a source of energy other than that generated by the human body for that purpose or by gravity, and acting by changing the density of or converting that energy. A manual IV drip bag is not Rule 12. A pump-driven IV set is. Second, the device has to administer or remove a medicinal product, a body liquid, or another substance. The three-way list is broad on purpose. It catches insulin, saline, blood, plasma, waste, bile, air, oxygen, and anything else that moves through a tube or lumen under power.

The default is Class IIa. The escalation to Class IIb is controlled by three named criteria, applied together: nature of the substances, part of the body, mode of application. Any one of the three can push the device to Class IIb if it introduces potential hazard. In practice, serious delivery devices rarely stay in Class IIa for long — most end up at Class IIb after honest analysis, because at least one of the three criteria produces hazard.

Article 51 of the MDR is the framework article that makes Annex VIII binding. MDCG 2021-24 (October 2021) is the authoritative interpretation guide and contains worked examples for the active device family including Rule 12.

Typical Rule 12 devices — and what class they usually land in

The following are the canonical Rule 12 devices. The classes cited below are the ones that typically hold after analysis, not promises.

Infusion pumps (general, ambulatory, syringe, volumetric). Class IIb in most cases. The escalation usually comes from the nature of the substances — cytostatics, high-concentration electrolytes, vasoactive drugs — or from the mode of application at high accuracy in intensive care.

Insulin pumps, including wearable patch pumps. Class IIb. Insulin is a substance where under- or over-delivery can cause immediate, serious harm. The mode of application (continuous subcutaneous, often closed-loop with a sensor) makes error recovery difficult.

Dialysis machines (haemodialysis, peritoneal dialysis cyclers, haemofiltration). Class IIb. Both administration (dialysate, replacement fluids) and removal (waste, ultrafiltrate) are in scope. The part of the body (vascular access or peritoneum) and the volume of exchange push the hazard analysis firmly to IIb.

Anaesthesia delivery systems and vaporisers (where active). Class IIb. Nature of the substance (anaesthetic gases) and mode of application combine to make any misdelivery potentially catastrophic.

Enteral feeding pumps. Typically Class IIb when used for patients who cannot tolerate misdelivery (neonates, ICU patients), Class IIa for simple ambulatory adult enteral feeding in some configurations. The analysis turns on the patient population and the specific substances.

Suction devices (medical, surgical, tracheal). Class IIa by default, escalating to Class IIb when used on central airways or in configurations where loss of suction or over-suction creates immediate danger.

Negative pressure wound therapy devices. Rule 12 or Rule 9 depending on intended purpose and mode of action; when they are characterised primarily as removing exudate under active pressure, Rule 12 applies, and the class depends on the wound type and duration.

Drug-delivery inhalers (active, powered). Rule 20 usually takes precedence for inhaled medicinal products via body orifices, but active nebulisers with sophisticated dosing control may fall under Rule 12 depending on how the intended purpose is written. This is a place where the rule selection itself has to be defended.

Do not treat these as verdicts. They are the starting point. The class of a specific device is determined by its specific intended purpose, its specific substances, and its specific mode of application — applied against the real Rule 12 text.

How to apply Rule 12 step by step

The Rule 12 analysis is a short, structured exercise. Run it in this order and document each step.

Step 1 — Confirm the device is active. Read the Annex VIII Section 1 definition of an active device. If the device is not active, Rule 12 does not apply and the analysis moves to the invasive or non-invasive families.

Step 2 — Confirm the device administers or removes substances. Read the intended purpose. Does the device move a medicinal product, a body liquid, or another substance into or out of the body under power? If yes, Rule 12 applies. If the device only provides energy without moving substances, Rule 9 applies instead.

Step 3 — Write the intended purpose in the Article 2(12) sense. MDR Article 2(12) defines intended purpose as "the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials or statements, and as specified by the manufacturer in the clinical evaluation." Write it down as one paragraph, internally consistent across all four information sources. Every downstream Rule 12 criterion runs against this text.

Step 4 — Apply the three hazard criteria, each in its own paragraph.

  • Nature of the substances. Identify every substance the device can administer or remove. For each, ask: what happens if this is delivered too fast, too slow, in the wrong concentration, or not at all? A substance where error produces immediate serious harm (insulin, vasopressors, anaesthetics, cytostatics, high-potassium electrolytes) pushes the device toward Class IIb.
  • Part of the body concerned. Identify the anatomical site of administration or removal. Central circulatory system, central nervous system, intracardiac, intrathecal, and intra-arterial routes are inherently higher hazard than peripheral subcutaneous or external. Pulmonary and vascular sites generally push toward Class IIb.
  • Mode of application. Is the device used continuously or in discrete doses? At home or in the ICU? Open-loop or closed-loop with sensor feedback? Does the user recover from an error easily or is an error likely to go unnoticed? Continuous, unattended, closed-loop, or high-flow modes push toward Class IIb.

Step 5 — Aggregate the three criteria and decide. If any of the three criteria produces a substantive hazard that a rational clinician would call "potentially hazardous," the device is Class IIb. If all three are genuinely low-hazard, the device is Class IIa. "Low-hazard" here does not mean "we think it is safe." Every medical device is intended to be safe. It means that the specific combination of substance, site, and mode does not create a realistic pathway to serious harm from administration or removal error.

Step 6 — Cross-check against the implementing rules in Annex VIII Section 2. If another rule also applies to the device (for example, Rule 9 for energy exchange, or Rule 22 for a closed-loop therapeutic system with integrated diagnosis), the highest-class-wins principle applies. Rule 22 in particular catches closed-loop drug delivery systems at Class III. Do not stop at Rule 12 if another rule also catches the device.

Step 7 — Document the decision. The classification output is not "Class IIb." It is "Class IIb under Annex VIII Rule 12, based on [intended purpose paragraph], because [substance analysis], because [site analysis], because [mode of application analysis], cross-checked against [other applicable rules]." Anything shorter cannot be defended to a Notified Body auditor.

Common Rule 12 misclassifications

Defaulting to Class IIa because "the pump just moves liquid." The pump is not what gets classified. The intended purpose is. A pump whose intended purpose is delivering insulin at a specific rate to a specific patient population is not "just moving liquid."

Ignoring one or more of the three criteria. Founders frequently analyse the nature of the substance carefully and then skip the mode of application. The three criteria are cumulative. Any one of them can escalate the class.

Using the "but the drug is already approved" argument to drop a class. The approval status of the medicinal product is not a Rule 12 criterion. Rule 12 asks about the hazard of administration or removal, not the drug approval pathway.

Treating Rule 12 as mutually exclusive with Rule 9. Active therapeutic devices that exchange energy fall under Rule 9. Active devices that administer or remove substances fall under Rule 12. Many real devices do both. When both apply, the highest class wins, per the implementing rules in Annex VIII Section 2.

Missing Rule 22 for closed-loop systems. A device that automatically adjusts drug delivery based on integrated sensor data — for example, an artificial pancreas closed-loop system — is caught by Rule 22 at Class III in addition to Rule 12. The Rule 22 escalation overrides the Rule 12 result.

Writing the classification without naming the substance, site, and mode. A Notified Body auditor will ask for all three. "Class IIb under Rule 12" is not a classification. "Class IIb under Rule 12 because of [these specific facts]" is.

The combination product boundary — Rule 12 vs. medicinal product regulation

Rule 12 sits next to the combination product boundary in Article 1(8) and Article 1(9) of the MDR. The boundary decides whether the product is regulated as a medical device under the MDR at all, or as a medicinal product under Directive 2001/83/EC.

The short version: if the device and the medicinal product form a single integral product intended exclusively for use in the given combination and not reusable, and if the action of the medicinal product is principal, the whole product is regulated as a medicinal product. The device part is assessed for safety and performance against the relevant general safety and performance requirements in Annex I of the MDR, but the marketing authorisation is a medicinal product authorisation, not a CE certificate.

If the action of the device is principal and the medicinal product is ancillary, the product is a device. If the medicinal substance is incorporated as an integral part with ancillary action, Rule 14 of Annex VIII applies and the device is Class III.

If the device and the medicinal product are separate — an infusion pump that a hospital fills with a drug purchased separately — the device is a device and Rule 12 applies to it. This is the most common Rule 12 situation and the one most startups face.

The boundary matters because the wrong side of it wastes quarters of work. A founder who starts an MDR conformity assessment on a product that turns out to be a medicinal-product-with-ancillary-device has built the wrong technical file for the wrong regulator. Walk the boundary deliberately, in writing, before committing to Rule 12 as the classification anchor.

The Subtract to Ship angle on Rule 12

The Subtract to Ship framework for MDR compliance treats classification as the second of four passes, after the Purpose Pass and before the Evidence Pass. For a Rule 12 device, the subtraction move inside the Classification Pass is not "find the lowest class we can argue for" — it is "identify the correct class with supporting evidence, and then cut every activity that belongs to a higher class than the one that applies."

For a Class IIb infusion pump, that usually means not building the Class III clinical investigation plan that a cautious consultant might recommend on general principle. The clinical evaluation under Article 61 is rigorous for Class IIb, but it is not the Class III pathway. Subtract the Class III activities that do not apply.

For a Class IIa suction device, it means not building the IIb-depth PMS plan unless the mode of application actually escalates. Subtract the IIb activities that do not apply.

Subtract to Ship never means hiding from Class IIb to claim Class IIa. The three Rule 12 criteria are specific. If any of them produces hazard, the device is IIb and the IIb workload is not optional. The framework prevents paying for Class III when Class IIb is the correct answer — and it prevents building a IIa file when the honest analysis is IIb.

Reality Check — Have you applied Rule 12 correctly?

  1. Can you quote the Rule 12 text from Annex VIII, Section 3, and identify the three hazard criteria by name?
  2. Have you confirmed the device is active in the Annex VIII Section 1 sense, not just "electric"?
  3. Have you listed every substance the device can administer or remove, and done a hazard analysis for each?
  4. Have you identified the anatomical site or sites of administration or removal and assessed their hazard level?
  5. Have you characterised the mode of application — continuous vs. discrete, open-loop vs. closed-loop, attended vs. unattended, home vs. clinical?
  6. Have you checked whether Rule 9 (energy exchange), Rule 22 (closed-loop therapeutic), or any special rule also catches the device?
  7. Have you walked the combination product boundary in Article 1(8)-(9) to confirm the product is a device and not a medicinal product?
  8. Have you documented the classification with the specific substance, site, mode, and rule citation, so a Notified Body auditor can follow the logic in one read?

Frequently Asked Questions

Is every infusion pump Class IIb under MDR Rule 12? Most infusion pumps end up at Class IIb after the Rule 12 analysis, but not automatically. The class depends on the three hazard criteria — nature of the substance, part of the body, mode of application — applied to the specific pump. A simple ambulatory pump delivering a benign substance in a low-hazard configuration could, in principle, stay at Class IIa, though this is rare. Document the decision against the three criteria and do not rely on the default verdict.

What is the difference between Rule 9 and Rule 12 for active devices? Rule 9 covers active therapeutic devices that administer or exchange energy with the body — electrosurgery, therapeutic lasers, ultrasound therapy. Rule 12 covers active devices that administer or remove substances. Many real devices do both and are caught by both. When multiple rules apply, the highest class wins under the Annex VIII Section 2 implementing rules.

Does Rule 12 apply to dialysis machines? Yes. Dialysis machines both administer substances (dialysate, replacement fluids) and remove them (waste, ultrafiltrate), and they are active. Rule 12 applies, and the analysis almost always produces Class IIb because of the volume of exchange, the vascular or peritoneal site, and the continuous mode of application.

How does Rule 12 interact with Rule 22 for closed-loop drug delivery? Rule 22 classifies active therapeutic devices with an integrated or incorporated diagnostic function that significantly determines patient management — such as closed-loop systems — as Class III. A closed-loop insulin delivery system that automatically adjusts dosing based on sensor data is caught by both Rule 12 and Rule 22. Under the highest-class-wins implementing rule in Annex VIII Section 2, the Class III result from Rule 22 overrides the Class IIb result from Rule 12.

Is a manual IV drip set a Rule 12 device? No. A gravity-driven IV drip set is not active in the Annex VIII Section 1 sense, because it operates by gravity rather than by a source of energy other than that generated by the human body. Manual IV sets are classified under the non-invasive or invasive rules, depending on their specific characteristics.

What documentation does a Notified Body expect for a Rule 12 classification? The Notified Body expects a classification statement that cites Annex VIII Rule 12, identifies the intended purpose per Article 2(12), names the substances administered or removed, identifies the anatomical sites, characterises the mode of application, and concludes on the class with a paragraph of reasoning. Bonus points for a cross-check paragraph against Rule 9, Rule 22, and any applicable special rules. MDCG 2021-24 worked examples are the reference point for the level of detail expected.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 2(12) (intended purpose), Article 51 (classification), Annex VIII Section 1 (definitions), Section 2 (implementing rules), and Section 3 Rule 12 (active devices intended to administer or remove medicinal products, body liquids, or other substances). Official Journal L 117, 5.5.2017.
  2. MDCG 2021-24 — Guidance on classification of medical devices, October 2021 (Medical Device Coordination Group).

This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The Rule 12 walkthrough above is the orientation layer — the classification of a specific active delivery or removal device must always be made against the full text of Annex VIII Rule 12, cross-checked with MDCG 2021-24, and documented with the specific substance, site, and mode of application. When a Rule 12 analysis sits close to the combination product boundary, or close to Rule 22 for closed-loop systems, a classification working session with a sparring partner who has run the exercise across fifty-plus certifications is usually the fastest path to a defensible answer.